[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-bladder-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-bladder-diseases":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100396486","bladder-fiducial-markers-and-multiparametric-mri-mp-mri-to-optimize-bladder-chemo-radiotherapy-100396486",false,"NCT04442724","Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy","FMBRT","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of primary urothelial carcinoma of the bladder. Subjects with mixed histology are required to have a dominant traditional cell carcinoma (TCC) pattern.\n* Clinical stage T2-T4a, Nx, M0 considered appropriate for, and electing to receive, chemoradiation of the bladder\n* Planned TURBT as part of the normal course treatment, to take place prior to the initiation of chemo irradiation\n* Adequate renal function: Serum creatinine \\\u003C 2 mg\u002FdL OR calculated creatinine clearance (CrCl) \\> 30ml\u002Fmin\n* Ability to understand and willingness to sign a written informed consent\n* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during study participation, and for 90 days after study treatment discontinuation\n\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n\nExclusion Criteria:\n\n* Subjects with primary TCC of the ureter, urethra, or renal pelvis, without TCC of the bladder, are not allowed\n* Known distant metastatic disease (e.g. pulmonary or hepatic metastases)\n\n  * Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadenectomy with the goal of complete resection of all malignant disease are allowed\n* Patients with bladder abnormalities that preclude safe placement of fiducial markers (i.e. abundant large diverticuli or cellules, active or recurrent urinary infection)\n* Planned (or prior history of) definitive bladder irradiation\n* Intravesical chemo- or biologic therapy within 6 weeks of first treatment\n* Any planned neoadjuvant systemic immunotherapy. Note that prior bacille Calmette-Guerin vaccine (BCG) is not an exclusion\n* Clinically significant active infection or uncontrolled medical condition that would preclude participation in study\n* Pregnant or nursing women are excluded\n* Previous malignancy other than TCC that, in the opinion of the treating investigator, is likely to interfere with protocol treatment\n* Individuals with severe renal failure and cannot receive MRI contrast","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI imaging technology can help with detection of bladder cancer earlier and more accurately when evidence of bladder cancer is not visible by scope.",[26,27,28,29,30],"Bladder Cancer","Urinary Bladder Neoplasm","Urologic Neoplasms","Neoplasms","Urinary Bladder Diseases",[32,33],"Fiducial marker","Fiducial marker guided technique","RECRUITING","2025-08-11",{"date":37,"type":38},"2025-08-14","ACTUAL",{"date":40,"type":38},"2020-07-01",{"date":42,"type":20},"2026-06-30",{"name":44,"class":45},"Cedars-Sinai Medical Center","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100451068","infectious-complications-after-cystectomy-a-prospective-observational-study-100451068","NCT05153694","Infectious Complications After Cystectomy: A Prospective Observational Study","Inclusion Criteria:\n\n* Disease which requires removal of the urinary bladder\n\nExclusion Criteria:\n\n* Patient does not want to participate",{"count":54,"type":20},200,"OBSERVATIONAL","Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. This study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and serial measurements of infectious markers pre- and post-operatively. In-hospital complications are meticulously recorded, and long-term outcomes assessed through structured follow-up interviews at 3, 6, and 12 months. These follow-ups utilize standardized questionnaires to evaluate post-discharge infectious complications and gather patients' perspectives on their in-hospital experiences, providing a robust understanding of both clinical outcomes and patient-reported experiences.",[26,58,59,60,61,62,30,63],"Infections","Infection, Bacterial","Infection, Hospital","Infection Wound","Urinary Tract Infections","Urinary Tract Disease","2024-09-13",{"date":66,"type":38},"2024-09-19",{"date":68,"type":38},"2021-12-01",{"date":70,"type":20},"2025-12-31",{"name":72,"class":45},"Ludwig-Maximilians - University of Munich",1]